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CrystalAdeno-associated viruses (AAVs) are leading candidate vectors for human gene therapy. AAV serotypes have
broad cellular tropism and use a variety of cellular receptors. AAV serotype 3 binds to heparan sulfate
proteoglycan prior to cell entry and is serologically distinct from other serotypes. The capsid features that
distinguish AAV-3B from other serotypes are poorly understood. The structure of AAV-3B has been
determined to 2.6 Å resolution from twinned crystals of an infectious virus. The most distinctive structural
features are located in regions implicated in receptor and antibody binding, providing insights into the cell
entry mechanisms and antigenic nature of AAVs. We show that AAV-3B has a lower afﬁnity for heparin than
AAV-2, which can be rationalized by the distinct features of the AAV-3B capsid. The structure of AAV-3B
provides an additional foundation for the future engineering of improved gene therapy vectors with
modiﬁed receptor binding or antigenic characteristics.and Molecular Biology, School
ce University, 3181 S.W. Sam
+1 503 494 8393.
n).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Adeno-associated viruses (AAV) have emerged as leading gene
therapy candidate vectors. Cited advantages include lack of disease
associated with the virus, the ability to transduce non-dividing cells,
absence of an adverse immunological response, and long-term
expression of therapeutic payload (Buning et al., 2004; Raake et al.,
2008). Despite these attributes, AAVs have broad cell and tissue
tropism, low transduction efﬁciency, and are neutralized by a pre-
sensitized host immune system (Halbert et al., 1997), limiting the
therapeutic potential of vectors based on natural serotypes. Improved
AAV-based vectors can be designed more efﬁciently with an under-
standing of the structure and functions of natural virus capsids.
Adeno-associated viruses are small (∼250 Å) non-enveloped
parvoviruses with a 4.7 kb single-stranded DNA genome packaged
inside a protein capsid of T=1 icosahedral (60-fold) symmetry
(Chapman and Agbandje-McKenna, 2006). Parvoviruses of the genus
Dependovirus, such as AAV, depend in replication upon co-infection
with a helper virus, such as adenovirus (Bowles et al., 2006). The AAV
genome contains two genes, encoding capsid and replication proteins.
Multiple start codons and alternate mRNA splicing give rise to 3
overlapping capsid proteins (VP1, VP2, and VP3). Capsid proteins
differ only at their N-termini and are present in a 1:1:8 ratio. VP1contains a unique N-terminal region of ∼137 amino acids, followed by
a 65 amino acid region, common to VP1 and VP2. The VP3 protein
contains ∼534 amino acids (depending on the serotype), common to
all 3 capsid proteins.
12 AAV serotypes (and hundreds of natural variants thereof) have
been identiﬁed (Gao et al., 2004; Schmidt et al., 2008). In spite of the
high sequence identity of their genomes (53–93%), AAV serotypes are
antigenically distinct from one another and use a range of different
receptors for cell binding and entry (Akache et al., 2006; Asokan et al.,
2006; Qing et al., 1999; Rutledge et al., 1998; Seiler et al., 2006;
Summerford et al., 1999; Summerford and Samulski, 1998), which
contribute to widely different cell speciﬁcities among serotypes. AAV
serotype 3 was isolated from a human clinical specimen (Muramatsu
et al., 1996) and has somewhat different cell tropism compared to other
serotypes (Handa et al., 2000; Liu et al., 2005; Rabinowitz et al., 2002).
AAV-3B is a minor variant of AAV-3 (also known as AAV-3A), with 6
amino acid differences in the VP1 capsid protein (Rutledge et al., 1998),
4 of which are in VP3. Cell entry by AAV-3B is not inhibited by neu-
tralizing rabbit anti-AAV-2 serum, demonstrating that these 2 serotypes
are antigenically distinct (Rutledge et al., 1998). Although anti-AAV-2
serum does not efﬁciently neutralize AAV-3 cell entry, some conforma-
tion-speciﬁc monoclonal antibodies raised against the AAV-2 capsid are
cross-reactivewith AAV-3 (Wobus et al., 2000). This suggests structural
conservation of some epitopes on the two capsids. Other monoclonal
antibodies (such as C37-B) speciﬁcally inhibit receptor binding by AAV-
2, and are not cross-reactive with other serotypes (Wobus et al., 2000).
The effect of structural differences on antibody cross-reactivity among
AAV serotypes is not fully understood.
Table 1
Summary of diffraction data and reﬁnement statistics.
Parameter Crystal 1 Crystal 2
Space group R3 R3






Resolution range (Å)a 14–3.0 (3.07–3.00) 15–2.6 (2.66–2.60)
Twin fraction 0.15 0.48
Rmerge (%)b 6.7 (9.4) 6.6 (42.2)
Completeness (%) 10.9 (10) 28.1 (10)
Rcryst c 0.23 {0.24} (0.42) 0.19 (0.38)
Rfree c 0.26 {0.27} (0.46) 0.22 (0.36)
RMSD bond lengths (Å)/RMSD bond
angles (°)
0.003/0.694 0.003/0.746
No. protein/nucleotide atoms 4154/22 (x 20) 4154/22 (x 20)
Avg. B-factor (Å2) 105.9 90.6
Estimated error (Luzzati, Å) 0.95 0.57
a Numbers in parentheses are values in highest resolution shell.
b Rmerge =∑hkl∑ijIi hklð Þ− bI hklð Þ Nj =∑hkl∑i Ii hklð Þ, where Ii(hkl) is the ith ob-
servation of a symmetry equivalent of reﬂection hkl. The highest resolution shell has no
symmetry equivalent reﬂections, and therefore Rmerge was calculated in medium
resolution shells (4.7–4.3 Å for crystal 1 and 2.9–2.8 Å for crystal 2).
c Rcryst/Rfree in brackets were determined without the twin law (h, -h-k, -l). Rfree was
calculated with 2822 (4.4% of data from crystal 1) and 5095 (4% of data from crystal 2)
reﬂections, selected from identical thin resolutions shells from each data set.
Reﬂections neighboring test set resolution shells were omitted to reduce bias in Rfree.
As a result, the highest resolution shell for which Rfree was calculated was 3.23–3.17 Å
for crystal 1 and 2.8–2.75 Å for crystal 2.
27T.F. Lerch et al. / Virology 403 (2010) 26–36In spite of high sequence identity between some of the AAV
serotypes, there are important functional differences beyond their
antigenic properties. Comparative studies therefore have the potential
to shed important light on, for example, the determinants of cell
tropism/speciﬁcity. AAV-3B is most closely related in sequence to AAV-
2, sharing 87% capsid identity to the type species. AAV-2 is the most
widely characterized serotype, and its crystal structure was the ﬁrst to
be determined among AAVs (Xie et al., 2002). Subsequently, crystal
structures of AAV-4 (Govindasamyet al., 2006) and -8 (Namet al., 2007)
and a cryo-EM structure of AAV-5 (Walters et al., 2004) have been
determined. Crystal structures of serotypes 1, 5–7, and 9 are also in
progress (DiMattia et al., 2005; Miller et al., 2006; Mitchell et al., 2009;
Quesada et al., 2007; Xie et al., 2008). All serotypes have a core β-barrel
subunit fold, which is highly conserved among all parvoviruses of
known structure (Chapman and Agbandje-McKenna, 2006). The AAV
capsid surface topology arises from loops that connect the core beta
strands of each subunit, generating distinctive features including
protruding spikes surrounding the 3-fold symmetry axis; a cylindrical
protrusion surrounding the pore near the 5-fold symmetry axis; and a
dimple near the 2-fold symmetry axis. Differences in the intervening
loops of AAV-2, -4, and -8 lead to unique capsid structural features,
whichpresumably contribute to serotype-speciﬁc receptor interactions,
immune recognition, cell tropism and transduction efﬁciency.
AAV-2 and -3 require heparan sulfate proteoglycan (HSPG) for cell
attachment (Handa et al., 2000; Rabinowitz et al., 2002; Summerford
and Samulski, 1998), while serotypes 1, 4, 5, 6 bind to speciﬁc sialic
acid derivatives prior to cell entry (Kaludov et al., 2001; Wu et al.,
2006). AAV-6 can also bind heparan sulfate, but it is sialic acid binding
that facilitates cell entry. AAV-3 has a weaker afﬁnity for heparin than
AAV-2, as higher concentrations of heparin are required to inhibit cell
entry (Handa et al., 2000). This is due, presumably, to incomplete
conservation of the heparin binding site identiﬁed on AAV-2 (Kern
et al., 2003; Levy et al., 2009; Lochrie et al., 2006; O'Donnell et al.,
2009; Opie et al., 2003). Following attachment to HSPG, AAV-3 then
binds to a co-receptor before entering the cell through an endosomal
pathway. FGFR1 and the 37/67 kDa laminin receptor (LamR) have
been identiﬁed as co-receptors for both AAV-2 and AAV-3 (Akache
et al., 2006; Belur et al., 2008; Blackburn et al., 2006; Qing et al., 1999),
and the proposed binding motif on AAV-2 for another co-receptor,
α5β1 integrin, is conserved in serotypes 1–3 and 6–10 (Asokan et al.,
2006). In spite of this apparent overlap in co-receptor usage, AAV-3
did not compete with AAV-2 in cell entry assays, indicating that there
are distinct preferences in the receptors for cell entry (Mizukami et al.,
1996). In fact, a 42 kDa receptor that binds AAV-3 has been identiﬁed
that does not bind AAV-2 (Handa et al., 2000). Little is known about
how structural differences between serotypes contribute to heparin
binding afﬁnity or co-receptor selectivity among serotypes.
The functions of natural AAV capsids can be better understood
through their structures, which can also guide the future design of
novel recombinant gene therapy vectors. In an effort to more fully
understand receptor binding and antigenic determinants of AAVs, the
X-ray crystal structure of AAV-3B was undertaken. Although there is
high conservation of the protein fold etc., at a detailed level, critical
regions of the capsid surface have distinctive physical–chemical
properties. These differences suggest that the viruses have faced
selective pressures to ﬁnd a variety of means of binding to cellular
receptors and evading immune neutralization.
Results and discussion
The structure of AAV-3B
The structure of AAV-3B was determined to 2.6 Å resolution, in
an effort to elucidate features that are distinctive to this serotype
and how these features contribute to cell entry and host immune
response. The structure was determined from two crystals, whichdiffered in levels of merohedral twinning, preventing merging of
the data sets. Merohedral twinning is a condition in which a crystal
contains two domains that differ in molecular packing orientation.
Twinning can be difﬁcult to detect, as the diffraction patterns of the
two domains overlap exactly. A hybrid approach used each data set at
different points during the structure determination process (Lerch
et al., 2009). A preliminary structure was determined using the data
set that was less complete (∼11%) and of lower resolution (3.0 Å), but
that came from a crystal with a lower twin fraction, making structure
determination tractable. This structure was then iteratively reﬁned
and modeled using the 28% complete 2.6 Å resolution data set, which
was nearly perfectly twinned (twin fraction of 0.48). Electron density
maps calculated using the 3.0 Å data, which were processed as if
untwinned, were sufﬁcient to build an initial model, even though
partially twinned (twin fraction of ∼0.15). Subsequent reﬁnement of
the model against this data set did take twinning into account. This is
reﬂected in the reﬁnement statistics shown in Table 1. In spite of
incomplete data and twinning, the 2.6 Å electron density map used to
build the ﬁnal AAV-3B model was of high quality (Fig. 1A) as a result
of 20-fold non-crystallographic symmetry (NCS) averaging. The AAV-
3B model contains amino acids 217 to 734 (VP1 numbering),
representing all but the ﬁrst 14 residues of the VP3 protein, and one
nucleotide molecule. The N-terminal residues are likely disordered or
distinct between subunits, as noted in prior parvovirus structures
(Govindasamy et al., 2006; Nam et al., 2007). Similarly, regions unique
to the N-termini of VP1 or VP2 proteins were not observed. These N-
terminal extensions are absent in ∼83% of the subunits, thus
structural information is lost during NCS averaging. (Furthermore,
there is no evidence that the outer surface of the capsid reﬂects the
locations of VP1-unique extensions inside the virus. Therefore, the
crystal lattice contains many orientations of the VP1-unique region
that are consistent with 60-fold symmetric packing interactions. The
diffraction data inherently reﬂect the average of the many VP1
orientations.) The ﬁnal Rcryst/Rfree values are 0.24/0.27 for the 3.0 Å
data (Rcryst/Rfree=0.23/0.26 when reﬁned as twinned). For the 2.6 Å
(twinned) data the ﬁnal Rcryst/Rfree values are 0.19/0.22 after
restrained reﬁnement of coordinates, individual restrained B-factors
for protein atoms and occupancy for the nucleotide (Table 1). Test
reﬂections for the calculation of Rfree were selected from thin
Fig. 1. The structure of AAV-3B. (A) A portion of the 2mFo-DFc electron density surrounding part of the AAV-3B model shows the quality of the map calculated at 2.6 Å resolution.
(B) The jellyroll barrel subunit architecture of AAV-3B is conserved throughout the Parvovirus family. A cartoon representation of a single subunit is shown, surrounded by the
transparent surfaces of neighboring subunits of the assembled capsid. Arrows mark the locations of the 5-, 3-, and 2-fold symmetry axes and are labeled. Loops are named after the
core β-strands that they connect. The DE loop lines the interior of the 5-fold pore and forms the cylindrical protrusion surrounding the pore of the intact capsid (also shown in C). The
HI loop covers part of the surface on the adjacent subunit (chain E), lining the ﬂoor of a depression surrounding the cylinder. Two sections of each GH loop and two loops from
neighboring subunit C comprise the prominent spikes that surround each 3-fold symmetry axis of the capsid. (C) Sixty AAV-3B subunits assemble to form the icosahedrally
symmetric virus capsid. The viral asymmetric unit is bounded by 5-fold (pentagon), 3-fold (triangle), and 2-fold (oval) axes. The features on the capsid surface are formed by the
subunit loops, shown in panel B.
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occurs in the presence of twinning and high non-crystallographic
symmetry (NCS) (Fabiola et al., 2006). Reﬂections that neighbor
the test reﬂections were also removed prior to reﬁnement, as these
are most strongly correlated with the test set and bias Rfree in the
presence of NCS. The structures determined from two different
crystals are very similar. The root mean squared deviation (RMSD)
between the structures is 0.5 Å, which is similar to the estimated
coordinate error (0.6 Å) of the 2.6 Å resolution structure. Thus, thestructures can be considered the same, and, forthwith, the 2.6 Å
resolution structure of AAV-3B is described, except as noted.
The AAV-3B subunit fold (Fig. 1B) is a jellyroll barrel conserved in
all parvoviruses. The eight core β-strands (βB through βI) are bridged
by loops, which are variable among parvoviruses and AAV serotypes.
These loops are named after the β-strands that they connect and some
contain additional secondary structural elements (Chapman and
Agbandje-McKenna, 2006). 60 identical copies of the AAV-3B subunit
form the icosahedrally symmetric capsid (Fig. 1C), where loops from
Fig. 2. Nucleotide binding inside the AAV-3B capsid, near the 3-fold symmetry axis. A
single dAMP nucleotide was modeled in a pocket at the interior of the AAV-3B capsid.
The nucleotide is a fragment of the genomic single-stranded DNA that, through
interactions with the capsid protein, adopts the capsid's icosahedral symmetry. Thus,
unlike most of the genomic DNA, its density remains strong through the symmetry
averaging applied during the structure determination. The interior surface of one capsid
subunit is shown in light pink, and the surfaces of 3-fold symmetric subunits are shown
in light blue and light green. The dark grey mesh shows the 2.6 Å mFo-DFc difference
map (within 1.5 Å of dAMP atoms), calculated with nucleotide coordinates omitted
from the phasing model and contoured at 3.3σ. The light grey mesh shows a 2mFo-DFc
electron density map calculated using the 2.6 Å data contoured at 1σ. Residues near the
dAMP binding site are shown as sticks and are labeled. Density was also observed in an
averaged map calculated using the untwinned 3.0 Å data (not shown).
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features. Like other AAV serotypes (Govindasamy et al., 2006; Nam et
al., 2007; Xie et al., 2002), the AAV-3B capsid surface has several
notable features: three prominent spikes surrounding each icosahe-
dral three-fold symmetry axis; a pore surrounded by a more subtle
cylindrical protrusion at the 5-fold symmetry axis; and a depression
(or dimple) at the 2-fold symmetry axis. The 3-fold symmetric spikes
are formed by two GH sub-loops from one subunit (AAV-3B VP1
residues 447–462 and 581–593) intertwined with two sub-loops
(residues 490–508 and 544–558) from neighboring subunit C (green
surface in Fig. 1B). Surrounding the 5-fold symmetry axis, the DE loop
(between strands βD and βE; residues 318–334) lines the pore and
forms the cylindrical protrusion. The ﬂoor of the depression
surrounding the 5-fold cylinder is formed by the HI loop (residues
652–673) from neighboring subunit H (yellow surface in Fig. 1B). The
bottom of the depression (“dimple”) at the 2-fold axis is the region on
the surface nearest to the viral center and consists of two α-helical
regions from adjacent subunits (blue and pink; subunit B).
On the interior of the AAV-3B capsid, clear electron density was
observed for one nucleotide, modeled as dAMP (Fig. 2). Some
smearing or disorder in the density is expected, because there is no
constraint that the base-type be adenine in all of the sites averaged
according to the icosahedral symmetry. The nucleotide is positioned
within a pocket at the interior surface of the capsid near the 3-fold
symmetry axis, beneath the exterior spikes. The pocket is lined by
residues 628–638 and 418–419 (VP1 numbering, Fig. 2). Nucleotide
coordinates were reﬁned to a fractional occupancy of ∼0.7 against the
higher resolution twinned data when ﬁxing the nucleotide B-factors
to the average for the capsid protein.In AAV-3B there appears to be a preference for adenosine
nucleotides, the size of the density indicating a predominance of
purines over pyrimidines, and the shape consistent with a C6 amino
group, but not C2. However, it is possible that the density represents a
symmetry averaged mixture with a small proportion of other base-
types. The viral genome is not icosahedrally symmetric. Thus,
resolution of the nucleotide density, following symmetry averaging
indicates that interactions with the capsid force a small piece of the
nucleic acid to conform to the capsid's icosahedral symmetry. A
nucleotide in the same position and orientation has been observed
previously in the structure of AAV-4 (Govindasamy et al., 2006), but
the nucleotide in AAV-8 is oriented differently (Nam et al., 2007).
Residues with side-chains directed toward the nucleotide in each
structure are fully conserved among AAV serotypes (compared to
b65% sequence identity for the interior surface of all AAV capsids) so
the site might have functional importance. It is noted that this
nucleotide (and its 60 symmetry-equivalents) is a smaller fraction of
the genome, and located in a different position from the oligo-
nucleotides observed in the autonomous parvoviruses, CPV and MVM
(Agbandje-McKenna et al., 1998; Chapman and Rossmann, 1995).
Comparing AAV-3B to other AAV serotypes of known structure
When the AAV-3B structure is compared to the structures of AAV-
2, -4, and -8 (Govindasamy et al., 2006; Nam et al., 2007; Xie et al.,
2002) (Fig. 3), one is ﬁrst struck by similarity in the backbone path
that is perhaps higher than their sequence identities might suggest.
Nevertheless, the structural differences between serotypes are in
proportion to their sequence dissimilarity. The capsid contains three
proteins (VP1, VP2, and VP3) of 736, 599 and 534 residues, in 1:1:8
ratio, differing only in their N-terminal extensions. As in the prior AAV
structures, the unique regions of VP1/2 are not resolved in the
icosahedrally averaged density. Interpretable density starts at VP3
residue 15 (residue 217 in the conventional VP1 numbering). Thus,
structural differences are quantiﬁed as the rootmean square deviation
(RMSD) between paired Cα atoms for the 520 resolvable residues of
VP3 (AAV-3B VP1 217–736). Each of the other serotypes was
superimposed on AAV-3B using the iterative SSM algorithm. This
starts with secondary structure matching, then extends the alignment
using both structure and sequence (Krissinel and Henrick, 2004).
Structurally AAV-3B is most similar to AAV-2 (88% capsid
sequence identity; RMS Cα difference of 0.57 Å for 500 of 520 AAV-
3B alignable residues). Estimated coordinate errors of ∼0.6 Å
(Table 1) would be expected to give an all-atom RMSD of 0.8 Å. As
the Cα positions, used in comparing structures of different sequence,
are determinedmore precisely, the consistency of error estimates and
RMSDs indicates that much of the modest difference between
coordinate sets is due to experimental error. AAV-8 (86% sequence
identity) is only slightly less similar structurally, where 508 of the
AAV-3B/8 residues can be aligned with an RMSD of 0.72 Å. AAV-3B is
the most different structurally from AAV-4 (63% sequence identity),
with 472 of 520 residues aligning with an RMSD 1.0 Å.
In all of the pair-wise structural alignments, the vast majority of
VP3 can be superimposed. Residues that could not be aligned are at
the N- and C-termini and also within a subset of nine structurally
variable regions (VR-I–IX), described previously as deviating by at
least 1 Å between the AAV-2 and AAV-4 structures (Govindasamy et
al., 2006). Between the AAV-2 and AAV-3B structures, these variable
regions differ signiﬁcantly (RMSDN1 Å) in only two regions, VR-I and
VR-IV (Table 2). Thus, for the most part, AAV-3B differs from AAV-4 in
the same places as does AAV-2, with similar magnitudes of deviation.
When AAV-3B is compared to AAV-8, a very similar picture emerges,
that the VR loops are similar except in VR-I and VR-IV, where the
differences are slightly greater than between AAV-3B and AAV-2.
Within the core viral jellyroll β-barrel, the structures of AAV serotypes
are exceptionally well conserved, even between AAV-3B and AAV-4,
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Table 2
RMSDs of residues in variable regions (Å).








I 1.3 3.0 3.2 2.6
II 0.9 1.6 0.9 1.6
III 0.8 1.8 0.7 2.1
IV 2.8 6.9 2.6 6.0
V 0.9 2.4 0.8 2.8
VI 0.8 4.3 0.8 3.7
VII 0.8 2.4 0.7 2.3
VIII 0.7 1.5 0.7 1.7
IX 0.9 2.9 1.0 2.6
Structures were initially aligned using SSM (Krissinel and Henrick, 2004). Residues that
remained unpaired by SSM were aligned manually to give the lowest RMSD for the
variable region of the loop.
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In the following paragraphs, variable regions (VR) I and IV, which are
the most distinct (RMSDN1 Å) between serotypes 2, 3B and 8 are
analyzed in greater detail.
VR-I contains residues 262–268 on the surface of AAV-3B, which
are identical in the sequence of AAV-2. Part of this region in AAV-2
(corresponding to AAV-3B residues 265–271) has been implicated
genetically in transduction efﬁciency in a step that is independent of
attachment to heparan sulfate (Lochrie et al., 2006). The structural
differences between serotypes 2 and 3B in VR-I appear to result from
different interactions that anchor one end of VR-I to its neighbors. In
AAV-3B, Asn270 hydrogen bonds with Ser472. By contrast, the corre-
sponding residues in AAV-2, Asp269 and Arg471 form a salt bridge. The
different sizes of Ser (AAV-3B) and Arg (AAV-2) affect the 269-to-471
backbone distance, resulting in interactions that are unique to AAV-2:
between Asn270 Nδ2 and Ser468 Obackbone, and between Asn268 Nδ2 and
Gly512 Obackbone. Within the VR-I residues, the interactions of AAV-3B
are analogous to AAV-2 with Ser262 and Ser267 hydrogen-bonding
with His271. This is in contrast to AAV-8, the outlier of the three
serotypes, in which a threonine replaces His271. The more exposed
AAV-8 loop is 2 residues longer with B-factors that are ∼2-fold higher
than the average (Nam et al., 2007). Thus, AAV-8 differs fromAAV-3B/
2 both in structure and ﬂexibility of VR-I. In summary, the local VR-I
primary structure is not distinctive between AAV-3B and AAV-2, but
tertiary interactions with regions distant in primary structure
differentiate the serotypes in a manner that is apparent only with 3-
D structure.
Variable region IV on AAV-3B (residues 449–469) is the region that
differs most from AAV-2, -4 and -8, and is located at the tip of the
spike (Fig. 3B). In all serotypes, the base of the loop is formed by a β-
ribbon. AAV-3B has the short β-ribbon of AAV-4 and AAV-8 rather
than the extended ribbon of its closest relative, AAV-2. The loop is
therefore less constrained by secondary structure than in AAV-2. The
loop extends outwards to form the sharp spike of AAV-8 rather than
folded down in the blunter version of AAV-4 (Fig. 3A). Relative to
AAV-2, the spikes are slightly splayed out with Cα–Cα distances
between 3-fold equivalents of 68 Å at Thr455, compared to 61 Å for
AAV-2. VR-IV is distinct in all AAV structures to date. Perhaps this
exposed and antibody-accessible region has been under particularly
stringent selective pressure to change to evade immune detection,
and that its exposed location has provided more freedom to do so
without collateral impact on neighboring structural elements.
To this point, the analysis has been framed mostly in terms of
backbone structure. Differences in sequence add to this and modulate
the surface characteristics, evenwhere the backbone is conserved. This
is important as we analyze the structural determinants of serotype-
speciﬁc functional attributes.
The receptor binding site
The mechanism by which AAV-3B attaches to heparan sulfate
proteoglycan (HSPG) on the cell surface is not fully understood. For
AAV-2, there is now a wealth of structural and genetic evidence about
these interactions at the amino acid level. Inferences into the
mechanism of heparan binding by AAV-3B can bemade by integrating
our more comprehensive understanding of AAV-2 receptor interac-
tions with the structure of AAV-3B. Implicit in such an approach is the
assumption that binding of the primary receptor shares commonalities
in the two serotypes. With 87% sequence identity, prima facie, this is
not an unreasonable assumption. With this important caveat, theFig. 3. Comparing AAV serotype structures. (A) Molecular surfaces calculated from the ato
outlined and is bounded by a 5-fold symmetry axis (pentagon), two 3-fold axes (triangles), a
differences in the subunit loop structures at “VR-I” (dashed circle) and “VR-IV” (solid circle)
matching (SSM) algorithm (Krissinel and Henrick, 2004): AAV-3B (blue), -2 (Xie et al., 20
greatest differences are in two of the variable regions (VR), I and IV.heparin density can be superimposed with the precision with which
the structures can be aligned (∼0.6 Å), but interpretation is limited
by the 8 Å resolution of the AAV-2 cryo-EM, corresponding to the
dimensions of 1 or 2 amino acids. In functional measures of receptor
binding, serotypes 2 and3 appear similar, but differ in detail. They both
enter the cell after initial attachment to heparan sulfate proteoglycan
(Rabinowitz et al., 2002; Summerford and Samulski, 1998), but AAV-3
appears to have a lower afﬁnity for heparin than AAV-2 (Handa et al.,
2000). Similar to AAV-3A, characterized in previous studies, AAV-3B
also has a lower heparin binding afﬁnity than AAV-2, based onweaker
binding to a heparin afﬁnity column (Fig. S1).
Heparin and heparan sulfate are highly sulfated, and thus
negatively charged molecules. Heparin binding sites on proteins are
typically positively charged, due to the presence of basic (arginine and
lysine) residues (Conrad, 1998). Mutagenesis of AAV-2 has identiﬁed
5 basic residues involved in heparin binding (Kern et al., 2003; Opie et
al., 2003), including arginines 585 and 588 in AAV-2 whose mutation
to alanine eliminated binding to heparin altogether (Opie et al., 2003).
These residues are located within VR-VIII on the side of each 3-fold
proximal spike on the surface of AAV-2 (Fig. 4A). The recent ∼8 Å
cryo-electron microscopy (EM) structure of AAV-2 in complex with
heparin revealed two important features of the AAV-2 heparin
binding site (O'Donnell et al., 2009). Firstly, the complex provided
independent conﬁrmation of the importance of Arg585 and Arg588 in
contacting heparin. The strongest heparin electron density was
located in contact with these residues. Secondly, the structure
revealed that the overall heparin-binding footprint on AAV-2 is
much broader than previously appreciated, spanning 36 total amino
acids (including the 5 previously identiﬁed). This includes residues
that contact heparin directly or have unobstructed (through solvent)
access to heparin (Fig. 4A). The surface topology of the heparin-
binding region on AAV-2 is very similar to the analogous region on
AAV-3B (Fig. 4B). Analysis of the electrostatic surface potential in this
region, however, reveals striking differences between these serotypes.
We were encouraged to analyze the surface electrostatics of AAV-
3B, given the success of the electrostatic-based prediction of the AAV-
2 heparan-binding site (Xie et al., 2002), which has now been
conﬁrmed experimentally (O'Donnell et al., 2009). Potentials were
calculated and mapped onto the surfaces of AAV-2 (Fig. 4C) and AAV-
3B (Fig. 4D), highlighting the contributions of sequence differences to
surface charge in these two serotypes. In the AAV-2:heparin complex
(O'Donnell et al., 2009), the strongest heparin density was centered
over the most positively charged patch, anchored by Arg585 and
Arg588. The corresponding region in AAV-3B is more neutral, as Arg585mic structures of AAV-3B, -2, -4, and -8. The triangular icosahedral asymmetric unit is
nd a 2-fold axis (oval). The most distinctive surface features correspond to the greatest
as illustrated in panel B. (B) Capsid subunits are overlaid with the secondary structure
02; red), -4 (Govindasamy et al., 2006; purple), and -8 (Nam et al., 2007; green). The
Fig. 4. Structural insights into receptor binding. Three of the sixty spikes on AAV-2 (A and C) and AAV-3B (B and D) are rendered as molecular surfaces. (A) Residues that have been
shown previously to contact heparin directly (blue) or indirectly (teal) on AAV-2 are colored (O'Donnell et al., 2009). Residues within the heparin binding footprint that are not
conserved in AAV-3B are shaded lighter than conserved residues. (B) Residues from AAV-3B that align with the heparin contact residues in AAV-2 are similarly colored and shaded.
The loss of the positive charge of R585 and R588 of AAV-2might be partly compensated by the presence of R594 and/or R447 of AAV-3B. The electrostatic potential of AAV-2 (C) and
AAV-3B (D) mapped onto the respective capsid surfaces is shown. Difference electron density for heparin bound to AAV-2, contoured at 7.5σ (∼5 estimated error units), is
superimposed (O'Donnell et al., 2009). The strongest density for the sulfonated heparin (negatively charged) was observed immediately adjacent to R585 and R588 of AAV-2 (C). (D)
The corresponding region on the AAV-3B spike is less electro-positive. Two distinct basic patches on AAV-3B, one near R594 and the other near residue R447, are farther from the
strongest heparin density seen in AAV-2, but are containedwithin (R594) or adjacent to (R447) the heparin binding footprint. The positive region that contains R447 is located on the
opposite side of the spike relative to R585/R588 on AAV-2, and is most clearly seen here on the side of the 3-fold symmetric spike 3.
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which form the most intimate heparin contacts in AAV-2, are not
conserved in other heparin-binding serotypes, although this could
account for AAV-2's stronger binding. Based on differences in the
charge distribution in this region, it is likely that heparin binds AAV-
3B somewhat differently than it does AAV-2.
Although the main determinant of heparin attachment is likely
distinct on AAV-3B, we cannot exclude the possibility that, like AAV-2,
heparin binds to AAV-3B in the general vicinity of the 3-fold spikes.
The substitutions for Arg585/Arg588 are polar in AAV-3B (Ser586 and
Thr589), residues that are also common in heparin-binding sites
(Conrad, 1998). Two distinct positive patches, created in part by
residues Arg594 and Arg447, are located near the 3-fold axis on AAV-3B
and might compensate, in part, for the loss of Arg585/Arg588 (Fig. 4D).
The ﬁrst site is located at the center of the 3-fold axis, where
symmetry-equivalents of Arg594 from three different subunits come
together (Figs. 4B and D). Arg594 is unique to AAV-3B and extends thepositively charged zone into the region between the 3-fold proximal
peaks. Furthermore, its bulk, relative to the alanine of AAV-2, raises
the surface towards where heparin is seen to bind in AAV-2
(O'Donnell et al., 2009). Arg594 would not directly contact the heparin
as seen in AAV-2, but it is adjacent to Arg485 which would have
solvent-mediated access. The presence of Arg594 extends positive
surface charge from just below the locations of Arg585 and Arg588 in
AAV-2 to the 3-fold axis. Curiously, amino acid 594 is one of six that
are different between AAV-3B (Arg) and AAV-3A (Gly). As AAV-3A
also binds to heparin (Handa et al., 2000; Rabinowitz et al., 2002),
Arg594 cannot be the sole determinant for heparin binding.
A second possibility is that Arg447 couldmake up for the absence of
AAV-2's Arg585/Arg588 in AAV-3B. Arg447 is conserved in AAV-2, but its
charge is neutralized in AAV-2 by Glu499. This is not the case in AAV-
3B (and AAV-3A), where an uncharged asparagine (Asn500) occupies
the same position as Glu499 in AAV-2. The positively charged surface at
Arg447 in AAV-3B is on the side of the spike, opposite the heparin
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of Arg585/Arg588.
In summary, the surface topologies of AAV-3B and AAV-2 are
similar, and there is more than enough positively charged surface in
the general area for favorable interactions with a negatively charged
primary receptor. We might expect that heparin binding be similar,
but not exactly the same, as the charge distribution differs in detail. In
particular, it is noted that the greatest positive charge is no longer
midway up the side of the 3-fold proximal peak, but closer to the
valley ﬂoor (when comparing AAV-3B to AAV-2). It is plausible that
heparin might sit lower in the valley in AAV-3B to take advantage of
this. With differences emerging in the details of the heparin binding
sites as homologous structures are determined, it appears that
evolution has found several variations on a theme that are all
acceptable solutions to receptor binding. Apparently the exact details
do not matter critically for the virus to enter the cell.
Antigenic regions
Insights into AAV evolution and immune evasion can be gained by
comparing the structures of AAV-3B and AAV-2. With their highFig. 5. Speciﬁcity of MAb C37-B binding. A close-up view of a single 3-fold proximal spike on
charge close to the mimotope of C37-B (AAV-2 residues 492–501, shown as sticks). C37-B bl
representations of two subunits (grey and yellow) are shown inside of a semi-transparent s
and VR-VIII (protruding GH loops, labeled) from a neighboring subunit. The dimensions of a
3B) and N496 (AAV-2) in panels E and F, illustrating that C37-B would likely cover part of VR
receptor binding to this serotype.homology, similar receptor-binding properties, and likelihood that
immune selective pressure has led to faster divergence at neutralizing
immunogenic sites (Chapman and Rossmann, 1993; Rossmann and
Palmenberg, 1988), many of the differences in surface characteristics
are likely to be antigenic determinants. Such differences might be
indicative of ways that structure could account for the inability of
polyclonal anti-AAV-2 serum to neutralize AAV-3B (Rutledge et al.,
1998). When AAV structures are compared, it is the three-fold
symmetric spikes that have the largest changes, and, as these regions
are highly exposed, they therefore likely represent antigenic hot-spots
on the capsid.
Linear peptide epitopes (mimotopes) on AAV-2 have been
identiﬁed for several neutralizing monoclonal antibodies (mAbs),
including C37-B, which displays speciﬁcity for AAV-2 and does not
bind to AAV-3 (Wobus et al., 2000). C37-B neutralizes AAV-2 at a step
prior to cellular binding (Wobus et al., 2000), presumably by
competing for HSPG binding. Structural differences between AAV-3B
and AAV-2 offer a potential explanation for C37-B speciﬁcity (Fig. 5).
One stretch of amino acids (493–502 of AAV-2; Figs. 5B and D) was
found to be the dominant contributor to the epitope (Wobus et al.,
2000). The sequence of this C37-B mimotope differs in AAV-3B by 4AAV-3B (A and C) and on AAV-2 (B and D) shows differences in surface topology and
ocks receptor binding to AAV-2, but does not bind AAV-3 (Wobus et al., 2000). Cartoon
urface, colored by electrostatic potential. The mimotope is sandwiched between VR-IV
typical antibody footprint are drawn as a 30 Å diameter circle, centered at N497 (AAV-
-IV and VR-VIII, including R585/R588 on AAV-2, perhaps explaining how C37-B blocks
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these four amino acid substitutions, because the surface topology
adjacent to the mimotope (in the context of the assembled virion) is
noticeably different. The local topology depends on substantial (6 Å)
differences in a neighboring loop, VR-IV. The surface neighboring the
C37-B mimotope is much more concave in AAV-2 than in AAV-3B
(Figs. 5A and B), perhaps forming a more intimate interface with a
convex antibody FAb. Furthermore, the surface charge distribution
near the mimotope is different between AAV-2 and AAV-3B. In AAV-2
it is more negatively charged, while in AAV-3B the mimotope is
adjacent to a positively charged region centered at Arg447 (described
above). Typical epitopes have a diameter of ∼15–30 Å (Smith and
Moser, 1997). Thus, it is likely that C37-B interacts not only with the
mimotope peptide, but with variable regions VR-IV and VIII from the
GH loop of an adjacent subunit that ﬂank it in the assembled capsid. A
30 Å-wide footprint would cover the tip of VR-VIII and one side of VR-
IV, encompassing the region where surface shape and charge differ
(Figs. 5C and D). In AAV-2, the C37-B footprint would likely include
Arg585 and Arg588 (Fig. 5D), explaining how C37-B inhibits receptor
binding. VR-IV adopts substantially different conformations in each
AAV serotype, andmight be the effective limitation on cross-reactivity
of C37-B-like neutralizing antibodies.
The limitations of peptide scanning technologies are well known,
that mimotope identiﬁcation relies on an isolated peptide fragment
adopting a near-native conformation. It is therefore to be expected
that, at best, only part of a conformational epitope will be correctly
identiﬁed. As the differences in the structure of the mimotope itself
are modest, it is likely that it is adjacent regions, refractory to pepscan
analysis, are the greater antigenic determinants. Particularly VR-IV,
that is immediately adjacent in the assembled virion, is seen in the
structure to be associated with changes to the local surface topology
and to the electrostatics that would be large enough to allow AAV-3B
to evade C37-B binding and subsequent neutralization.
Conclusions
Consistent with high sequence similarity, the subunit fold of AAV-
3B is similar to that of other AAV serotypes. However, differences in a
subset of surface-exposed loops give rise to surprisingly distinct
characteristics in the local surface topology and electrostatic charge of
AAV-3B in critical regions that, from the structure, appear to be the
determinants of the distinct receptor binding and immunogenic
properties of the virus. Indeed, comparing the structure of AAV-3B
with other serotypes shows the greatest structural diversity at
locations implicated in antibody binding (Wobus et al., 2000) and
polyclonal neutralization (Lochrie et al., 2006). Additionally, differ-
ences in the electrostatics on AAV-3B near the 3-fold symmetry axis
suggest that while AAV-3B binds heparin in the same general vicinity,
the speciﬁc interactions with its primary receptor are distinct from
those of AAV-2.
There are broad implications from the detailed differences that are
seen in the heparin binding site. Others have suggested that
polysaccharide binding is used by the virus to trigger conformational
changes that might be a part of cell entry (Asokan et al., 2006; Levy et
al., 2009). It is difﬁcult to see how the diversity in heparan sulfate
binding interactions could be consistent with conservation of the type
of precise triggeringmechanisms typically found in allosteric proteins.
Indeed our own visualization of an AAV-2:heparin complex indicated
that there were no large conformational changes (O'Donnell et al.,
2009). In fact, the structural diversity in the attachment sites for
HSPG-binding serotypes is more consistent with the use of heparan
sulfate by the virus as a passive anchor to maintain proximity to the
cell surface.
Studies of AAV-2 have demonstrated the inﬂuence of the
heparin-binding site on tissue tropism. In vectors based on AAV-2,
inclusion of the heparin binding site motif (585-RGNR-588) wasrequired for transduction restricted mainly to the liver (Grimm et al.,
2008), while substituting this peptide motif in AAV-2 with that from
a non-heparin binding serotype results in systemic gene transfer to
muscle tissue (Asokan et al., 2010). Moreover, insertion of peptide
ligands at the heparin binding site (amino acid position 587) of AAV-
2 can result in disruption of the native tropism, while simultaneous-
ly re-directing transduction to alternate tissues (Perabo et al., 2006).
The same might be true for AAV-3B, where a heparin-binding site
distinct from that on AAV-2 could be modiﬁed. The diversity with
which AAVs are able to assemble a functioning primary receptor
binding site is encouraging for those attempting to engineer changed
tropism through the receptor-binding speciﬁcity of AAV vectors. The
structure of AAV-3B provides a new template for the design of
vectors, where antigenic and receptor binding properties are distinct
from other serotypes.
Materials and methods
AAV-3B was produced and puriﬁed as described (Lerch et al.,
2009), following procedures optimized for AAV-2 (Xie et al., 2004). A
detailed description of the crystallization, data collection, processing
and preliminary analysis of AAV-3B crystals has been reported (Lerch
et al., 2009). Brieﬂy, two partial diffraction data sets were collected
from AAV-3B crystals at the Cornell High Energy Synchrotron Source
(CHESS) F1 beamline. The crystals belong to space group R3, diffracted
X-rays to 3.0 Å and 2.6 Å resolution, but cannot be merged well due to
different levels of merohedral twinning. Crystal twinning was
characterized for each data set using the program phenix.xtriage
(Adams et al., 2002). The crystal used to collect a 12% complete 3.0 Å
data set was partially twinned (twin fraction of 0.15), while a 32%
complete 2.6 Å data set came from a crystal that was near perfectly
twinned (twin fraction of ∼0.48), both by the twin law (h, -h-k, -l).
With long exposures needed to record intensities that are weak (in
proportion to the volume of the unit cell) and progressive radiation
damage it is common that virus crystals provide only a fraction a
complete data set. Given that a number of virus structures have been
determined with 10–30% complete data sets (Badger et al., 1988), the
varying level of twinning and therefore the intractability of merging
different data sets, it was decided to determine the structure with our
most complete (32%) data set, although the lesser twinned data set
would be helpful in early steps. Data collection and reﬁnement
statistics are shown in Table 1.
Test set reﬂections were selected from thin resolution shells, to
avoid bias due to high (20-fold) non-crystallographic symmetry
(NCS) (Fabiola et al., 2006) and twinning. The width of the shells
varied from 0.005 Å (at higher resolution) to 0.042 Å (at lower
resolution), to provide comparable numbers of test reﬂections in
each shell. For the 3.0 Å data set a total of 2822 reﬂections (4.4%)
were selected from 6 different resolution shells. To avoid bias when
alternating between data sets, the same 6 shells were used for the
higher resolution data set, plus an additional 2 shells between 3.0
and 2.6 Å. The test set for the higher resolution data contained the
5095 reﬂections (4%). In the presence of non-crystallographic
symmetry, signiﬁcant bias in Rfree can result from correlations
between test reﬂections and their neighbors in reciprocal space
unless the latter are also excluded from reﬁnement (Fabiola et al.,
2006). Thus, reﬂections were excluded from wider shells enclosing
each test shell — a total of 10,395 for the 3.0 Å data and 18,711 for
the 2.6 Å data.
As described previously (Lerch et al., 2009), the orientation of
AAV-3B in the unit cell was determined from the rotation function,
using the less twinned 3.0 Å data set and the program GLRF (Tong and
Rossmann, 1997). One-third of the capsid (20 subunits) is contained
in the asymmetric unit, and the starting model consisted of AAV-2,
oriented in the AAV-3B unit cell. The position of the particle was
constrained, with the icosahedral and crystallographic 3-fold
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optimized by rigid body reﬁnement using the program CNS (Brünger
et al., 1998).
Starting phases for icosahedrally averaged maps were calculated
at 3.75 Å resolution from the starting AAV-2 model and extended to
3.0 Å resolution with the Rave/CCP4 program suite (Collaborative
Computational Project Number 4, 1994) and the 3.0 Å data set,
disregarding the twinning. Initial electron density maps from the
3.0 Å data exhibited side chain and other structural features unique
to AAV-3B, and omit maps for regions omitted from the initial
phasingmodel were clearly interpretable, together verifying that the
NCS averaging was of sufﬁcient power to obtain unbiased density
from the partial data sets (Lerch et al., 2009). The AAV-3B sequence
was manually inserted and an initial model built using the program
O (Jones et al., 1991). Coordinate, B-factor, and nucleotide
occupancy reﬁnement against both 3.0 Å and 2.6 Å resolution data
was performed using the program phenix.reﬁne (Adams et al.,
2002), taking into account twinning of the 2.6 Å data. Subsequent
reﬁnement of the 3.0 Å model also took twinning into account,
although the twin fraction was likely negligible. The full content of
the asymmetric unit (20 subunits) was reﬁned with non-crystallo-
graphic symmetry (NCS) tightly restrained. Further model building
was performed using icosahedrally averaged detwinned electron
density maps (2.6 Å resolution) with sections of the model omitted
to remove bias. Final modeling (searches for water molecules,
addition of nucleotide, geometry optimization) was performed using
the program Coot (Emsley and Cowtan, 2004), and the model quality
was assessed with Procheck (Laskowski et al., 1993).
Comparison of the AAV-3B structure to AAV-2 (Xie et al., 2002;
PDB id 1LP3), -4 (Govindasamy et al., 2006; PDB id 2G8G), and -8
(Nam et al., 2007; PDB id 2QA0) structures was performed by
structural alignment using the secondary structure matching (SSM)
algorithm (Krissinel and Henrick, 2004) in Coot. Regions that could
not be aligned structurally (Cα atomic distance N5 Å) are deﬁned as
variable.
Electrostatic potentials of AAV-2 and -3B were calculated using the
programs PDB2PQR (Dolinsky et al., 2004) and APBS (Baker et al.,
2001). A course grid covered the entire capsid, while a ﬁne grid
(80 Å×80 Å×50 Å) was centered near a 3-fold symmetry axis,
covering one set of 3-fold symmetric spikes. The respective potentials
were mapped onto the molecular surfaces of AAV-2 and AAV-3B,
which were rendered in PyMOL (DeLano, 2002) with color ramps
between −5 and +5 kbT/ec. Images of individual AAV subunits and
full capsids were made using PyMOL (DeLano, 2002) and Chimera
(Pettersen et al., 2004) software, respectively.
The AAV-3B structures at 2.6 and 3.0 Å have been deposited in
the Protein Data Bank (PDB) with accession codes 3KIC and 3KIE,
respectively.
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